ClinicalTrials.gg
CompletedNCT06342778Updated Jul 11, 2025

Pharmacokinetics and Bioequivalence of Doxylamine+Pyridoxine and Diclectin Under Fed Conditions in Healthy Volunteers

A Phase 1 interventional study of Doxylamine + Pyridoxine and Diclectin in Nausea, sponsored by Valenta Pharm JSC. Completed at 1 site in Russia. Open to female participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-11.

Sponsored by Valenta Pharm JSC · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
Female
01

Study summary

This study aims to evaluate pharmacokinetic profile and establish bioequivalence of the investigational drug Doxylamine + Pyridoxine, enteric-soluble, film-coated tablets, 10 mg + 10 mg (Valenta Pharm JSC, Russia) compared to the reference drug Diclectin, delayed-release tablets, 10 mg + 10 mg (registration certificate holder - Tzamal Bio-Pharma, Israel, manufacturer - Duchesnay Inc, Canada) in healthy volunteers under fed conditions.

02

Conditions studied

  • Nausea

Browse trials for

03

In context

Nausea

644 studies on the registry are indexed under Nausea; 85 are open to participants now.

This study's enrollment of 28 is below the median of 96 across 544 interventional studies indexed under Nausea.

Browse Nausea studies →

Lead sponsor

Valenta Pharm JSC is the lead sponsor of 40 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary and personally signed form by the heathy subject prior to initiation of any study procedures.
  2. Women of (18 to 49 years inclusive).
  3. Verified "healthy" status with no abnormalities detected based on clinical, laboratory, and instrumental examinations specified in the study protocol.
  4. Blood pressure (BP) level: systolic blood pressure (SBP) from 100 to 139 mmHg, diastolic blood pressure (DBP) from 60 to 89 mmHg (inclusive).
  5. Heart rate (HR) from 60 to 90 beats per min (inclusive).
  6. Respiratory rate (RR) 12 to 18 breaths per min (inclusive).
  7. Body temperature from 36 to 36.9°C (inclusive).
  8. (BMI) of 18.5 ≤ BMI ≤ 30 kg/m², with body weight ≥ 45 kg.
  9. Consent to use adequate methods throughout the study and for 30 days after completion of the study, negative pregnancy test.
  10. Volunteers must demonstrate appropriate behavior and coherent speech.

Non-inclusion Criteria:

  1. Positive allergic history.
  2. History of to the active ingridient and/or of the study drugs.
  3. A history of drug intolerance to the active ingridient and/or excipients of the study medications.
  4. Chronic diseases of cardiovascular, lymphatic, respiratory, nervous, endocrine, digestive, musculoskeletal, integumentary, immune systems, as well as genitourinary apparatus and hematopoietic organs.
  5. deviations from normal reference values for laboratory and diadnostic parameters based on local laboratory standarts.
  6. History of gastrointestinal tract surgery (excluding appendectomy performed at least 1 year prior to screening).
  7. Diseases/conditions that, in the investigator's judgement, may affect the absorption, distribution, metabolism, or excretion of study drugs.
  8. Acute infectious diseases within 4 weeks prior to screening.
  9. Use of medications with significant effects on hemodynamics or those affecting liver fuction (barbiturates, benzodiazepines, omeprazole, cimetidine, etc.) within 1 month prior to screening.
  10. Regular use of medicatins within 3 weeks prir to screening or single-dose medication intake within 7 days prior to screening.
  11. Blood or plasma donation within 3 months prior to the Screening Visit.
  12. Use of hormonal contraceptives within 2 months prior to the Screening Visit.
  13. Use of depot injections of any medications within 3 months prior to the Screening Visit.
  14. Pregnancy or lactation period, positive pregnancy test.
  15. Participation in another clinical trial less than 3 months prior to screening or concurrently with the present study.
  16. Consumption of more than 10 units of alcohol (1 unit of alcohol is equivalent to 500 mL of beer, 200 mL of wine, or 50 mL of spirits) per week in the last month prior to inclusion in the study or history of alcoholism, drug abuse, or medicines abuse.
  17. Smoking.
  18. Positive blood test for antibodies to (HIV) types 1 and 2, antibodies to Treponema pallidum antigens, surface antigen (HBsAg), antibodies to virus antigens, rapid test (nasopharyngeal and/or oropharyngeal swab) for SARS-Cov-2 (COVID-19).
  19. Clinically significant abnormalities on (ECG).
  20. Positive urinalysis for narcotics and potent drugs.
  21. Positive breath alcohol vapor test.
  22. Scheduling a hospital stay during the study period, for any reason other than hospitalization required by this protocol.
  23. Inability or inability to comply with the requirements of the protocol, to follow the procedures prescribed by the protocol, to follow the diet, activity regime.
  24. Observance of religious fasting or special diet (e.g., vegetarian, vegan).
  25. Other conditions that, in the Investigator's judgement, may interfere with the volunteer's participation in the study or lead to early withdrawal, including lifestyle factors such as night shift work or extreme physical exertion.

Exclusion criteria

Exclusion criteria

  1. Refusal by the volunteer to continue participation in the study.
  2. Failure of the volunteer to comply with study protocol requirements, including missed visits, unauthorized use of prohibited medications, or non-adherence to dietary and lifestyle restrictions.
  3. Occurrence of safety-related issues during the study that endanger the subject (e.g. reactions, etc.).
  4. Volunteers included in the study in violation of the inclusion/non-inclusion criteria.
  5. Volunteer developing a severe and/or serious adverse event during the study.
  6. Missing collection of 2 or more consecutive blood samples, or 3 or more blood samples within a single period of pharmacokinetic part of the study.
  7. Occurrence of vomiting/diarrhea within 24 h after administration of the study drug (the choice of time interval is based on the value of tmax parameter for doxylamine and pyridoxal-5-phosphate, not exceeding 7.2 ± 1.9 and 11.7 ± 5.3 h, respectively, according to the manufacturer of the reference drug).
  8. Positive urine test for narcotics and potent drugs.
  9. Positive breath alcohol vapor test.
  10. A positive pregnancy test.
  11. A positive test for SARS-Cov-2 (COVID-19);
  12. Development of any new condition or situation that hinders protocol-defined procedures.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    RT-sequence

    Group 1 (14 volunteers, RT sequence) will take 2 tablets of Diclectin in Period 1 and 2 tablets of Doxylamine + Pyridoxine in Period 2

    Drug: Doxylamine + Pyridoxine · Drug: Diclectin

  • Active comparator
    TR-sequence

    Group 2 (14 volunteers, TR sequence) will take 2 tablets of Doxylamine + Pyridoxine in Period 1 and 2 tablets of Diclectin in Period 2

    Drug: Doxylamine + Pyridoxine · Drug: Diclectin

Interventions

  • DrugDoxylamine + Pyridoxine

    Drug pages: Doxylamine · Pyridoxine

    A single dose of R or T drug in each of 2 periods of the study under fed conditions

    Also known as: Doxylamine + Pyridoxine, enteric soluble film-coated tablets

  • DrugDiclectin

    A single dose of R or T drug in each of 2 periods of the study under fed conditions

    Also known as: Doxylamine + Pyridoxine, Delayed-release Tablets

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics - Cmax

    Maximum plasma concentration (Cmax) of doxylamine and pyridoxal-5-phosphate

    Time frame: From 0 to 72 hours (Day 1-4 and Day 15-18)

  2. Pharmacokinetics - tmax

    Time to reach Cmax (tmax) of doxylamine and pyridoxal-5-phosphate

    Time frame: From 0 to 72 hours (Day 1-4 and Day 15-18)

  3. Pharmacokinetics - AUC0-t

    Area under the plasma concentration-time curve from time 0 to t (AUC0-t) of doxylamine and pyridoxal-5-phosphate

    Time frame: From 0 to 72 hours (Day 1-4 and Day 15-18)

  4. Pharmacokinetics - AUC0-inf

    Area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf) of doxylamine and pyridoxal-5-phosphate

    Time frame: From 0 to 72 hours (Day 1-4 and Day 15-18)

  5. Pharmacokinetics - AUCextr

    Extrapolated AUC of doxylamine and pyridoxal-5-phosphate, defined as (AUC0-inf - AUC0-t)/AUC0-inf

    Time frame: From 0 to 72 hours (Day 1-4 and Day 15-18)

  6. Pharmacokinetics - t1/2

    Elimination half-life (t1/2) of doxylamine and pyridoxal-5-phosphate

    Time frame: From 0 to 72 hours (Day 1-4 and Day 15-18)

  7. Pharmacokinetics - kel

    Elimination constant (kel) of doxylamine and pyridoxal-5-phosphate

    Time frame: From 0 to 72 hours (Day 1-4 and Day 15-18)

  8. Pharmacokinetics - MRT

    Mean residence time (MRT) of doxylamine and pyridoxal-5-phosphate

    Time frame: From 0 to 72 hours (Day 1-4 and Day 15-18)

  9. Bioequivalence - ratio of Cmax

    Ratio of geometric mean Cmax for doxylamine and pyridoxal-5-phosphate after intake of R or T (with 90% confidence intervals)

    Time frame: From 0 to 72 hours (Day 1-4 and Day 15-18)

  10. Bioequivalence - ratio of AUC0-t

    Ratio of geometric mean AUC0-t for doxylamine and pyridoxal-5-phosphate after intake of R or T (with 90% confidence intervals)

    Time frame: From 0 to 72 hours (Day 1-4 and Day 15-18)

  11. Bioequivalence - ratio of AUC0-inf

    Ratio of geometric mean AUC0-inf for doxylamine and pyridoxal-5-phosphate after intake of R or T (with 90% confidence intervals)

    Time frame: From 0 to 72 hours (Day 1-4 and Day 15-18)

Secondary outcomes

  1. Adverse event type

    Adverse events will be assessed by complaints, results of physical examination, results of heart rate and blood pressure assessment, results of respiratory rate assessment, body temperature, laboratory monitoring (clinical blood count, biochemical blood count, urinalysis), electrocardiography; adverse events will be classified in accordance to MedDRA.

    Time frame: From Day - 14 to Day 0 (screening) to Day 22 ± 1 (end of the study)

  2. Adverse event frequency

    Number and frequency of adverse events registered during the study

    Time frame: From Day - 14 to Day 0 (screening) to Day 22 ± 1 (end of the study)

  3. Adverse event severety

    Severity of adverse events registered during the study

    Time frame: From Day - 14 to Day 0 (screening) to Day 22 ± 1 (end of the study)

07

Study locations

1 site
  • State budgetary health care institution Yaroslavl region "Clinical Hospital № 3"
    Yaroslavl, 150007, Russia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in May 2024, 2 months.

Of 18 phase 1 interventional studies under Nausea, half reached primary completion within 4 months of starting (the median); a quarter within 2 and three quarters within 8. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2024
First posted
Apr 2, 2024
StartActual
Feb 27, 2024
Primary completionActual
May 2, 2024
CompletionActual
May 2, 2024
Last update
Jul 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06342778
Lead sponsor
Valenta Pharm JSC
Responsible party
Sponsor
First posted
Apr 2, 2024
Start date
Feb 27, 2024
Primary completion
May 2, 2024
Completion
May 2, 2024
Last update
Jul 11, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Doxylamine · Pyridoxine

Start the discussion